We have provided over $2 billion in financing to over 500 life science companies. Our expertise in the life science and pharmaceutical industry allows us to underwrite the risks other lenders are not willing to assume. We are focused on long-term mutually beneficial relationships with our customers and venture capital partners.
While each business is unique, our customers typically have the following characteristics:
-
Experienced management teams
-
Strong business plan
-
Sufficient liquidity
-
Private companies with experienced venture capitalist backing
-
Public companies with successful fundraising records
-
Corporate collaborations
Customers we have recently worked with:
Acadia Pharmaceuticals, Inc.
Acorda Therapeutics
Acusphere, Inc.
Agensys, Inc.
Alexza Pharmaceuticals, Inc.
Alliance Medical Corporation
Amicus Therapeutics, Inc.
Amphastar Pharmaceuticals, Inc.
Anapharm
Arrow Therapeutics
Avanir Pharmaceuticals
Cellular Genomics, Inc.
Clarient Oncology, Inc.
CombinatoRx Incorporated
Corixa Corporation
Cyberkinetics, Inc.
Cytokinetics, Inc.
Dendreon
Diversa Corporation
Dyax Corp.
|
|
Favrille
FibroGen Inc.
GeneOhm Sciences, Inc.
Human Genome Sciences, Inc.
Isis Pharmaceuticals, Inc.
Nitromed, Inc.
Portola Pharmaceuticals, Inc.
Raven BioTechnologies Inc.
Renal Solutions, Inc.
Ricerca Biosciences LLC
Rigel Pharmaceuticals, Inc.
Vical Incorporated
Xenogen Corporation
Xenoport, Inc.
|
|
|